



**Company contact:** Maria Maccicchini, CEO  
QR Pharma, Inc.  
610 727 3710  
Maccicchini@qrpharma.com

## QR Pharma to Present at Massachusetts General Hospital

### Inhibition of amyloid precursor protein and alpha-synuclein improves memory and learning in a tg mouse model of Alzheimer's disease and normalizes non-movement symptoms in a tg mouse model of Parkinson's disease

*Berwyn, PA, March 4, 2014:* QR Pharma, Inc. (QR), a Phase 2 clinical stage specialty pharmaceutical company committed to developing therapeutics with novel approaches for the treatment of Parkinson's disease (PD), Alzheimer's disease (AD) and other neurodegenerative disorders, will make a presentation to the Neuroscience Department at Massachusetts General Hospital on Wednesday, March 5, 2014. Maria L. Maccicchini, Ph.D., CEO of QR, will discuss how QR's lead compound Posiphen® reverses learning problems in Alzheimer mice and the non-movement symptoms in Parkinson mice.

Posiphen has been shown to reverse the cognitive deterioration seen in transgenic (tg) AD mice (in collaboration with Columbia University) as well as inhibit the non-movement symptom - constipation - in tg PD mice (in collaboration with UCSF). Posiphen is the first drug to show amelioration in two different mouse models engineered with different toxic aggregating proteins to show AD or PD symptoms. Recent advances in the field of neurodegenerative disorders have found that several toxic proteins, including Abeta, tau, and alpha-synuclein among others, appear together and cause the cell death characteristic of these diseases. Posiphen has been found to reduce the levels of these toxic proteins back to normal level in various mice models as well as in humans with mild cognitive impairment and therefore is an excellent candidate for development in these neurodegenerative disease states.

**About Posiphen®:** QR's lead compound, Posiphen, is a small orally active compound with high blood brain barrier permeability. Posiphen reduces the levels of toxic proteins in the brains of patients with neurodegenerative disorders back to the levels found in normal healthy volunteers. By normalizing brain levels of alpha synuclein, beta amyloid and tau, it provides an avenue to treat a number of neurodegenerative disorders and attack the disease at the onset. QR expects Posiphen to influence the disease early so as to prevent the onset or diminish the severity of cognitive decline. Since neurotoxic proteins cause inflammation in the brain, lowering their levels reduces inflammatory factors and lowers inflammation.

**About QR Pharma, Inc.** Headquartered in Berwyn, Pennsylvania, QR Pharma, Inc. is a clinical-stage specialty pharmaceutical company committed to developing therapeutics with novel approaches for the treatment of cognitive impairment in neurological disorders. QR currently has three product development programs: Posiphen for early stage AD and PD, and BNC for advanced AD. For more information on QR Pharma, please visit the company's website, [www.qrpharma.com](http://www.qrpharma.com).

#### **Forward-Looking Statements:**

Certain statements in this press release or made by management from time to time regarding QR Pharma that are not historical facts are "forward-looking statements," as defined in the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks, assumptions and uncertainties that could cause actual future events or results to differ materially from such statements.

Contact: Contact: Maria L. Maccicchini, CEO  
Tel: 610 727 3710

10/14/2014

QR Pharma to Present at Massachusetts General Hospital

Fax: 610 727 4001

[maccecchini@qrpharma.com](mailto:maccecchini@qrpharma.com)

[www.qrpharma.com](http://www.qrpharma.com)

[Close this Window](#)